Evaluating clinical research : all that glitters is not gold
| Main Authors: | , |
|---|---|
| Format: | Book |
| Language: | English |
| Published: |
New York :
Springer Verlag ,
c2007
|
| Edition: | 2nd ed |
| Subjects: | |
| Online Access: | Table of contents only Publisher description |
Table of Contents:
- 1. What is the purpose of this book?
- 2. Why is benefit-to-harm balance essential to treatment decisions?
- 3. What are the strengths of randomized controlled clinical trials?
- 4. What are the weaknesses of randomized controlled clinical trials?
- 5. Do meta-analyses provide the ultimate truth?
- 6. What are the strengths of observational studies?
- 7. What are the weaknesses of observational studies?
- 8. Were the scientific questions stated in advance?
- 9. Were the treatment groups comparable initially?
- 10. Why is blinding/masking so important?
- 11. How is symptomatic improvement measured?
- 12. Is it really possible to assess quality of life?
- 13. What is the value of biologic markers in drug evaluation?
- 14. How are adverse drug reactions measured?
- 15. How representative are study subjects in clinical trials?
- 16. What happened to the study subjects who disappeared from the analysis?
- 17. How reliable are active-control trials?
- 18. How informative are composite outcomes?
- 19. Do changes in biologic markers predict clinical benefit?
- 20. How trustworthy are the authors?
- 21. Does publication in a reputable scientific journal guarantee quality?
- 22. Is it necessary to be a biostatistician to interpret scientific data?
- 23. Are all drugs of a class interchangeable?
- 24. How much confidence can be placed on economic analysis?
- 25. How should I handle the massive flow of information?
- 26. How well is research translated into clinical care?